AbbVie Inc. is reportedly close to an $11 billion all-cash acquisition of Apogee Therapeutics Inc., a move that would significantly expand the drug giant's anti-inflammatory drug pipeline. The deal, which could be announced as early as Monday, represents a roughly 60% premium over Apogee's closing share price of $90.38 on Thursday. This acquisition is part of a larger trend in the pharmaceutical industry, with approximately $200 billion in biotech buying sprees this year as companies like AbbVie look to bolster their drug pipelines.
Apogee's primary asset is zumilokibart, a long-acting anti-IL-13 antibody that is being developed as an alternative to Dupixent, a blockbuster inflammatory drug co-developed by Sanofi and Regeneron that generated $17.8 billion in revenue. While Dupixent requires biweekly injections, zumilokibart is being tested for administration every three to six months, potentially offering a significant advantage in patient convenience. Positive Phase 3 trial results for zumilokibart could position it to compete in the $200 billion global market for inflammatory conditions such as atopic dermatitis and asthma.
The acquisition aligns with AbbVie’s strategy to strengthen its immunology franchise, especially after its top-selling drug Humira faced patent expiration and increased competition from biosimilars. By adding a pipeline drug with the potential to rival Dupixent, AbbVie aims to reinforce its market position. The reported acquisition price of $10.9 billion values Apogee at several billion dollars above its pre-announcement market capitalization of approximately $6.81 billion, indicating AbbVie's high valuation of zumilokibart's potential. Analysts suggest that for this investment to pay off, zumilokibart would need to offer substantial advantages in dosing, efficacy, or treatment persistence, or expand into multiple indications.
